Cholestyramine
Cholestyramine, Locholest, Prevalite (cholestyramine) is a small molecule pharmaceutical. Cholestyramine was first approved as Questran on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cholestyramine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| QUESTRAN | Bristol Myers Squibb | N-016640 DISCN | 1982-01-01 | 2 products, RLD |
| QUESTRAN LIGHT | Bristol Myers Squibb | N-019669 DISCN | 1988-12-05 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cholestyramine | ANDA | 2024-01-25 |
| cholestyramine for oral suspension | ANDA | 2023-01-09 |
| cholestyramine light | ANDA | 2023-12-27 |
| cholestyramine powder for suspension | ANDA | 2023-10-23 |
| prevalite | ANDA | 2020-06-18 |
| promethazine hcl | New Drug Application | 2012-05-02 |
| questran | ANDA | 2019-11-01 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | — | 2 | — | 2 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | — | — | 1 | — | 1 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | 1 | — | 1 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | — | — | 1 | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | 1 | — | 1 |
| Hyperphosphatemia | D054559 | HP_0002905 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | HP_0003124 | — | — | 1 | 2 | — | 1 | 4 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | 3 | — | — | 4 |
| Coronary disease | D003327 | — | — | — | 1 | 3 | — | — | 4 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | 3 | — | — | 4 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 3 | — | — | 4 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | 2 | — | — | 3 |
| Graves disease | D006111 | EFO_0004237 | E05.0 | — | — | 1 | — | 1 | 2 |
| Hyperthyroidism | D006980 | — | E05.9 | — | — | 1 | — | — | 1 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | 1 | — | — | 1 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | — | 1 |
| Short bowel syndrome | D012778 | — | K90.82 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Microbiota | D064307 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Biliary liver cirrhosis | D008105 | — | K74.3 | 1 | — | — | — | — | 1 |
| Alagille syndrome | D016738 | EFO_0004151 | Q44.71 | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | — | — | — | — | — | — | 1 | 1 |
| Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | — | — | 1 | 1 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | — | — | — | — | 1 | 1 |
| Carotid stenosis | D016893 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cholestyramine |
| INN | colestyramine |
| Description | Colestyramine (INN) or cholestyramine (USAN) (trade names Questran, Questran Light, Cholybar, Olestyr) is a bile acid sequestrant, which binds bile in the gastrointestinal tract to prevent its reabsorption. It is a strong ion exchange resin, which means it can exchange its chloride anions with anionic bile acids in the gastrointestinal tract and bind them strongly in the resin matrix. The functional group of the anion exchange resin is a quaternary ammonium group attached to an inert styrene-divinylbenzene copolymer.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 11041-12-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201625 |
| ChEBI ID | — |
| PubChem CID | 70695640 |
| DrugBank | DB01432 |
| UNII ID | 4B33BGI082 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Cholestyramine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,137 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,908 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use